Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disorder caused by mutations in ADPKD1 or ADPKD2 genes. ADPKD1 gene mutations account for approximately 85 percent of cases; ADPKD2 gene mutations account for roughly 15 percent of cases. ADPKD1 is the most severe form of the disease; ADPKD2 patients develop kidney insufficiency about 20 years later. These mutations are passed down through families as an autosomal dominant trait. In about 10% of cases, the mutation occurs randomly and for no apparent reason (sporadically). ADPKD1 gene mutations are generally associated with more severe disease, an earlier age of onset, and an earlier age of onset of end-stage renal disease. The specific symptoms and their severity can vary significantly from person to person, even within the same family. Most affected people develop symptoms between the third and fifth decades of life. On the other hand, symptoms can appear during childhood or even infancy. The course is characterized by the development and inexorable expansion of multiple cysts scattered throughout the kidney parenchyma. The progressive loss of kidney function takes place over many decades and frequently leads to end-stage kidney disease during or after the sixth decade of life.
• ADPKD has an estimated prevalence of 40 to 48 cases per 100,000 population in the USA.

Thelansis’s “Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Autosomal Dominant Polycystic Kidney Disease (ADPKD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Autosomal Dominant Polycystic Kidney Disease (ADPKD), Autosomal Dominant Polycystic Kidney Disease (ADPKD) market outlook, Autosomal Dominant Polycystic Kidney Disease (ADPKD) competitive landscape, Autosomal Dominant Polycystic Kidney Disease (ADPKD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)